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Background: There is controversy whether nurse-administered, proceduralist-directed sedation with propofol is safe and effective with implantable 
cardioverter-defibrillator (ICD) placement.
Methods: We studied ICD implants where propofol was administered by nursing under the implanting electrophysiologist’s direction. Efficacy 
was assessed by % of ICD placement without emergent intervention. We assessed safety by a combined endpoint of serious (procedural deaths, 
unexpected transfer to CCU and respiratory failure requiring intubation) and non-serious (hypotension requiring fluid resuscitation and/or 
vasoconstrictors, and hypoxia requiring augmented respiratory support not intubation) adverse events.
Results: A total of 555 patients (pts) (age 63.7±14 yrs, 71.5% male) undergoing 576 procedures were evaluated from May 2006 to July 2009. 
Pts were NYHA Class I (16.8%), II (38.4%), III (41%) and IV (3.8%). ICD procedures included single/dual chamber (51.2%), biventricular (24.1%), 
and generator change (24.7%). Mean procedure time was 100±58 min and mean propofol dose was 460±401 (20-3130) mg. Midazolam was 
co-administered in 34.7% cases. In 98.4% cases, procedures were completed without an emergent intervention. Only 9 (1.6%) cases had serious 
events. Hypotension requiring fluid resuscitation and/or vasoconstrictors, and hypoxia requiring augmented respiratory support (not intubation) 
were seen in 92 (15%) and 163 (28.2%) cases respectively. With univariate analysis, lower EF (26±11% vs. 29±12%, p=0.016), higher propofol 
dose (570±453 mg vs 391±346 mg, p=0.002), propofol infusion vs. bolus (RR 3.5, CI 2.2-5.6, p=0.001), biventricular ICD (RR 3.00, CI 2.02-
4.44, P=0.001), 10% decrement in EF (RR 1.25, CI 1.1-1.4, P=0.016), and midazolam use (RR 0.5, CI 0.4-0.7, P=0.002) predicted events. With 
multivariate analysis, NYHA Class III/IV (RR 2.3, CI 1.5-3.4, p<0.001), longer procedure time per hour (RR 1.4, CI 1.1-1.8, P=0.006) and higher 
propofol dose per 100 mg (RR 1.07, CI 1.01-1.13, p=0.02) were independent predictors.
Conclusion: Sedation using propofol is safe and effective for ICD placement when administered by nursing. However, non-serious adverse events 
were common.
